First patent issued in Europe for Orexo's adrenaline product OX640
Orexo AB (publ.) announced on September 1, 2022, that the European Patent Office has granted a patent for OX640, its nasal adrenaline rescue medication. The patent (EP 3 962 455 B1) protects OX640 in Europe until May 2041, supporting Orexo's position in ongoing discussions with potential partners. CEO Nikolaj Sørensen emphasized the product’s innovation and market potential, alongside strong clinical data expected later this year. Orexo aims to enhance its patent portfolio for OX640 across various territories.
- Granting of European patent for OX640 until May 2041 enhances market potential.
- Recognition by the European Patent Office reinforces OX640's innovation.
- Strong clinical data anticipated later this year to support product viability.
- None.
UPPSALA, Sweden, Sept. 1, 2022 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the European Patent Office (EPO) has granted the first European patent specifically relating to OX640, Orexo's nasal adrenaline rescue medication based on the amorphOX® drug delivery platform.
The new patent, EP 3 962 455 B1, provides protection for the OX640 product in Europe until May 2041. Orexo has multiple patent applications filed in other territories and expect to continuously strengthen the patent portfolio for OX640.
Nikolaj Sørensen, President and CEO, said: "OX640 is a unique and innovative new product to be used for the emergency treatment of allergic reactions. I am pleased that the innovation has been recognized by the EPO, an important step towards making this life-saving medication available for patients in Europe. In addition to its excellent chemical stability, the clinical data that are anticipated later this year, and its significant market potential, securing strong patent protection for OX640 is clearly important for our discussions with potential partners."
For further information, please contact:
Orexo AB (publ.)
Nikolaj Sørensen, President and CEO | Lena Wange, IR & Communications Director | |
Tel: +46 (0)18 780 88 00 | Tel: +46 (0)18 780 88 00 | |
Email: ir@orexo.com | Email: ir@orexo.com |
About Orexo
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2021 amounted to SEK 565 million and the number of employees was 121. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.
For more information about Orexo please visit www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn, and YouTube.
The information was submitted for publication at 8 am CET, on September 1, 2022.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Orexo_Press_release_First Patent issued for OX640 in Europe_ Published Sep 1 2022 |
View original content:https://www.prnewswire.com/news-releases/first-patent-issued-in-europe-for-orexos-adrenaline-product-ox640-301616151.html
SOURCE Orexo
FAQ
What is the significance of the patent granted for OX640 by Orexo?
When was the patent for OX640 announced by Orexo?
What is the expected clinical data timeline for OX640?
How does the European patent impact Orexo's discussions with partners?
What are Orexo's future plans for its patent portfolio?
